We develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Headquarter Australia |
Countries of operation Australia |
Year founded 2022 (2 years) |
Funding status Private |
Company type SME |
Co-CEO
Office Manager
R&D Project Manager
Share capital injection/new funding: approx. USD 2,900,000